GGrantIndex
Sort

15,842 grants matching pancreatic cancer

Drug Development Core

$890,415
Daniel D Von Hoff · Translational Genomics Research Inst · P01 · FY2009 · CA

Cancer Immunotherapy Clinical Trials

$890,340
Julius Strauss · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

The role of intracellular pH in the specification of cell fate

$890,000
Todd Nystul · University Of California-San Francisco · · FY2020 · BIO

MOUSE CANCER MODELS VIA TGF-BETA RII LOSS

$888,503
Vanderbilt University · U01 · FY2003 · CA

Development of TIMP-2 derivatives or strategies as biologic therapies for cancer

$888,432
William Stetler-Stevenson · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Foregut Microbiome and Risk of Gastric Intestinal Metaplasia, and Gastric Cancer Risk

$888,388
Yu Chen · New York University School Of Medicine · R01 · FY2017 · CA

IGF::OT::IGF - IND ENABLING DEVELOPMENT OF NANOGMP: TARGETED

$888,375
Jun Li · Qualiber, Inc. · N44 · FY2014 · CA

FUNCTIONAL GENOMICS OF THE DEVELOPING ENDOCRINE PANCREAS

$888,089
Washington University · R24 · FY2001 · DK

Using Clinical Pharmacology Principles to Develop New Anticancer Therapies

$887,976
William Douglas Figg · Division Of Clinical Sciences - Nci · ZIC · FY2020 · CA

Identification of human tumor-associated antigens

$887,872
Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

Human natural killer cells: Advancing biology and clinical applications

$886,438
Michael A Caligiuri · Beckman Research Institute/City Of Hope · R35 · FY2025 · CA

Post-transcriptional control of Proliferation, Stress Response & Carcinogenesis

$886,074
Myriam Gorospe · National Institute On Aging · ZIA · FY2015 · AG

RAIT of Pancreatic Cancer with Humanized PAM4

$886,058
Ctr For Molecular Medicine/Immunology · R01 · FY2005 · CA

Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor Microenvironment

$885,794
Bumsoo Han · University Of Illinois At Urbana-Champaign · U01 · FY2024 · CA

Development of a companion diagnostic to identify patients who respond to microbiome-targeting drugs

$884,165
Bret David Wallace · Symberix, Inc. · R44 · FY2020 · GM

DIETARY INFLUENCE ON LIVER METASTASIS IN PANCREATIC CANCER

$883,531
Sloan-Kettering Institute For Cancer Research · · FY2022 · Department of the Army

Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer

$883,200
Subrata Sen · University Of Tx Md Anderson Can Ctr · U01 · FY2019 · CA

Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk

$882,433
Rohit N. Kulkarni · Joslin Diabetes Center · U01 · FY2025 · DK

SPORE in Pancreatic Cancer

$881,136
Donald J. Buchsbaum · University Of Alabama At Birmingham · P20 · FY2006 · CA

CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor Heterogeneity

$881,016
David Tuveson · Cold Spring Harbor Laboratory · U01 · FY2018 · CA

Targeting PKR-Bcl2 Signaling to Overcome Paclitaxel Resistance in Ovarian Cancer

$880,570
Jixin Dong · University Of Nebraska Medical Center · R01 · FY2025 · CA

INTERFERON E AS A TUMOR SUPPRESSOR AND POTENTIAL THERAPEUTIC IN PANCREATIC CANCER

$880,000
Sloan-Kettering Institute For Cancer Research · · FY2024 · Defense Health Agency

Next-Generation Antibody Discovery and Development Technology

$879,836
David Scott Johnson · Gigagen, Inc. · R44 · FY2016 · CA

The Antigen Targeting Core

$879,641
Maria Parkhurst · Division Of Basic Sciences - Nci · ZIC · FY2023 · CA

CANCER AND INFLAMMATION: FUNCTION AND THERAPY

$879,352
Michael Dean · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA